XSHE
002805
Market cap739mUSD
Oct 09, Last price
19.44CNY
1D
10.02%
1Q
-11.92%
Jan 2017
-18.56%
IPO
344.22%
Name
Shandong Fengyuan Chemical Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Shandong Fengyuan Chemical Co., Ltd. (SFCC) specializes in the development, manufacturing, and global distribution of a variety of chemical products. The company's core offerings include industrial and refined grades of oxalic acid, alongside numerous oxalate compounds, which it supplies to both Chinese domestic and international clients. Beyond these, SFCC's extensive product portfolio also features critical substances like potassium tetroxalate, lithium iron phosphate, potassium binoxalate, sodium nitrate, and essential lithium cathode materials. These chemical solutions are integral to a diverse range of industries and emerging sectors. They find vital applications in traditional fields such as pharmaceuticals, rare earth processing, fine chemicals, daily consumer products, and textile printing and dyeing. Furthermore, SFCC's products cater to cutting-edge areas including biopharmaceuticals, new energy vehicles, and environmental protection initiatives. Established in Zaozhuang, China, in the year 2000, the company has its headquarters in that location.
Key people
Xiaomeng Zhao
Chairman of the Board · since 2023
Lin Pang
Chief Financial Officer · since 2022
Yan Deng
General Manager, Director · since 2020
Fuxin Wan
Deputy General Manager · since 2025
Wenqin Ni
Secretary of the Board · since 2022
Lingguo Chen
Deputy General Manager, Director · since 2023
Cheng Zhao
Deputy General Manager, Director · since 2020
Fengqin Zhao
Director · since 2023
Tao Zhu
Staff Elected Director · since 2025
Yongcheng Jin
Independent Director · since 2021
Jian Li
Independent Director · since 2023
Shiyong Zhou
Independent Director · since 2020
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||||
Revenues | ||||||||||||
Cost of revenue | ||||||||||||
Unusual Expense (Income) | ||||||||||||
NOPBT | ||||||||||||
NOPBT Margin | ||||||||||||
Operating Taxes | ||||||||||||
Tax Rate | ||||||||||||
NOPAT | ||||||||||||
Net income | ||||||||||||
Dividends | ||||||||||||
Dividend yield | ||||||||||||
Proceeds from repurchase of equity | ||||||||||||
BB yield | ||||||||||||
| Debt | ||||||||||||
Debt current | ||||||||||||
Long-term debt | ||||||||||||
Deferred revenue | ||||||||||||
Other long-term liabilities | ||||||||||||
Net debt | ||||||||||||
| Cash flow | ||||||||||||
Cash from operating activities | ||||||||||||
CAPEX | ||||||||||||
Cash from investing activities | ||||||||||||
Cash from financing activities | ||||||||||||
FCF | ||||||||||||
| Balance | ||||||||||||
Cash | ||||||||||||
Long term investments | ||||||||||||
Excess cash | ||||||||||||
Stockholders' equity | ||||||||||||
Invested Capital | ||||||||||||
ROIC | ||||||||||||
ROCE | ||||||||||||
| EV | ||||||||||||
Common stock shares outstanding | ||||||||||||
Price | ||||||||||||
Market cap | ||||||||||||
EV | ||||||||||||
EBITDA | ||||||||||||
EV/EBITDA | ||||||||||||
Interest | ||||||||||||
Interest/NOPBT | ||||||||||||